Organon & Co. (NYSE:OGN) Trading Down 3.7%

Organon & Co. (NYSE:OGN) traded down 3.7% on Wednesday . The company traded as low as $19.77 and last traded at $19.78. 548,523 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 2,154,792 shares. The stock had previously closed at $20.55.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. downgraded shares of Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price target for the company from $18.00 to $20.00 in a report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Organon & Co. currently has a consensus rating of “Hold” and an average price target of $22.17.

Organon & Co. Stock Down 3.3 %

The firm’s fifty day moving average is $21.05 and its 200-day moving average is $20.07. The company has a current ratio of 1.64, a quick ratio of 1.17 and a debt-to-equity ratio of 60.05. The stock has a market capitalization of $5.12 billion, a P/E ratio of 5.02, a P/E/G ratio of 0.89 and a beta of 0.85.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. The business had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.61 billion. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The firm’s revenue for the quarter was down .1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.31 earnings per share. As a group, equities research analysts predict that Organon & Co. will post 4.14 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 5.64%. The ex-dividend date of this dividend was Friday, August 16th. Organon & Co.’s dividend payout ratio (DPR) is presently 27.38%.

Hedge Funds Weigh In On Organon & Co.

A number of hedge funds have recently added to or reduced their stakes in OGN. Vanguard Personalized Indexing Management LLC raised its stake in shares of Organon & Co. by 47.8% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 58,931 shares of the company’s stock valued at $850,000 after purchasing an additional 19,067 shares during the period. Quadrant Capital Group LLC boosted its position in shares of Organon & Co. by 1,222.3% during the fourth quarter. Quadrant Capital Group LLC now owns 11,464 shares of the company’s stock valued at $165,000 after buying an additional 10,597 shares during the last quarter. Norges Bank bought a new stake in Organon & Co. during the fourth quarter valued at approximately $26,321,000. Coldstream Capital Management Inc. purchased a new position in shares of Organon & Co. during the 4th quarter valued at $237,000. Finally, Quest Partners LLC purchased a new position in Organon & Co. during the 4th quarter valued at approximately $168,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.